Cochrane Abstracts
Risperidone for attention‐deficit hyperactivity disorder in people with intellectual disabilities Edited (no change to conclusions)
Risperidone for attention‐deficit hyperactivity disorder in people with intellectual disabilities Edited (no change to conclusions) is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Risperidone for Attention‐deficit Hyperactivity Disorder in People With Intellectual Disabilities Edited (no Change to Conclusions)." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434072/all/Risperidone_for_attention‐deficit_hyperactivity_disorder_in_people_with_intellectual_disabilities_Edited__no_change_to_conclusions_. Accessed 26 June 2022.
Risperidone for attention‐deficit hyperactivity disorder in people with intellectual disabilities Edited (no change to conclusions). Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434072/all/Risperidone_for_attention‐deficit_hyperactivity_disorder_in_people_with_intellectual_disabilities_Edited__no_change_to_conclusions_. Accessed June 26, 2022.
Risperidone for attention‐deficit hyperactivity disorder in people with intellectual disabilities Edited (no change to conclusions). In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/434072/all/Risperidone_for_attention‐deficit_hyperactivity_disorder_in_people_with_intellectual_disabilities_Edited__no_change_to_conclusions_
Risperidone for Attention‐deficit Hyperactivity Disorder in People With Intellectual Disabilities Edited (no Change to Conclusions) [Internet]. In: Cochrane Abstracts. [cited 2022 June 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434072/all/Risperidone_for_attention‐deficit_hyperactivity_disorder_in_people_with_intellectual_disabilities_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Risperidone for attention‐deficit hyperactivity disorder in people with intellectual disabilities Edited (no change to conclusions)
ID - 434072
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434072/all/Risperidone_for_attention‐deficit_hyperactivity_disorder_in_people_with_intellectual_disabilities_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -
